Slightly tangential to FDA March 2026 but Dr.PainCLE reminded me — what is the latest on the oral formulations?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Relevant to FDA March 2026 enforcement — here is my latest bloodwork comparison:

Key improvements: A1C 7.2% → 5.3%, triglycerides 207 → 107 mg/dL, hsCRP 6.0 → 1.3 mg/L. All on tirzepatide for 11 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Want to share my personal experience related to FDA March 2026 enforcement since I think it might help others in a similar situation.

I started my GLP-1 journey in October 2024 at 263 lbs with prediabetes and hypertension. My endocrinologist prescribed semaglutide 0.25mg to start.

Now, 10 months later: I am down 63 lbs, my labs have normalized, and I am off 2 of my 3 medications. The FDA March 2026 aspect specifically was something that made a big difference in my journey.

This community helped me every step of the way.

Relevant to FDA March 2026 enforcement — here is my latest bloodwork comparison:

Key improvements: A1C 8.4% → 5.5%, triglycerides 209 → 109 mg/dL, hsCRP 8.0 → 0.9 mg/L. All on tirzepatide for 13 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Want to share my personal experience related to FDA March 2026 enforcement since I think it might help others in a similar situation.

I started my GLP-1 journey in March 2025 at 280 lbs with metabolic syndrome. My telehealth provider prescribed semaglutide 0.25mg to start.

Now, 16 months later: I am down 70 lbs, my labs have normalized, and my sleep apnea has improved dramatically. The FDA March 2026 aspect specifically was something that made a big difference in my journey.

This forum was my go-to resource throughout.